Stephane Heymans

List of Publications by Year
in descending order

238 papers	35,691 citations	7096 78 h-index	3650 180 g-index
243 all docs	243 docs citations	243 times ranked	32183 citing authors

#	Article	IF	Citations
1	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
2	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
3	Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2013, 34, 2636-2648.	2.2	2,436
4	How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal, 2007, 28, 2539-2550.	2.2	2,302
5	2020 ESC Guidelines for the management of adult congenital heart disease. European Heart Journal, 2021, 42, 563-645.	2.2	971
6	Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genetics, 2001, 28, 131-138.	21.4	967
7	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
8	miR-133 and miR-30 Regulate Connective Tissue Growth Factor. Circulation Research, 2009, 104, 170-178.	4.5	763
9	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	2.2	757
10	Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nature Medicine, 1999, 5, 1135-1142.	30.7	745
11	Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease. Circulation: Cardiovascular Genetics, 2010, 3, 499-506.	5.1	683
12	Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nature Reviews Cardiology, 2021, 18, 169-193.	13.7	589
13	Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 2021, 42, 1554-1568.	2.2	434
14	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2011, 13, 1-10.	7.1	350
15	Acute viral myocarditis. European Heart Journal, 2008, 29, 2073-2082.	2.2	339
16	Myocardial Extracellular Matrix. Circulation Research, 2014, 114, 872-888.	4.5	301
17	Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. European Heart Journal, 2018, 39, 2704-2716.	2.2	300
18	Long noncoding RNAs in cardiac development and ageing. Nature Reviews Cardiology, 2015, 12, 415-425.	13.7	296

#	ARTICLE	IF	CITATIONS
19	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 119-129.	7.1	281
20	Increased Cardiac Expression of Tissue Inhibitor of Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-2 Is Related to Cardiac Fibrosis and Dysfunction in the Chronic Pressure-Overloaded Human Heart. Circulation, 2005, 112, 1136-1144.	1.6	267
21	The Quest for New Approaches inÂMyocarditis and InflammatoryÂCardiomyopathy. Journal of the American College of Cardiology, 2016, 68, 2348-2364.	2.8	257
22	Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs. European Heart Journal, 2015, 36, 353-368.	2.2	244
23	Use of Circulating MicroRNAs to Diagnose Acute Myocardial Infarction. Clinical Chemistry, 2012, 58, 559-567.	3.2	239
24	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 16-37.	7.1	239
25	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524.	7.1	234
26	Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window. Cardiovascular Research, 2006, 69, 604-613.	3.8	227
27	Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure. Circulation, 2013, 128, 1420-1432.	1.6	225
28	CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis. Journal of Molecular and Cellular Cardiology, 2015, 89, 98-112.	1.9	223
29	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure, 2019, 21, 827-843.	7.1	223
30	Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nature Medicine, 2011, 17, 1610-1618.	30.7	220
31	MicroRNAâ€18 and microRNAâ€19 regulate CTGF and TSPâ€1 expression in ageâ€related heart failure. Aging Cell, 2011, 10, 769-779.	6.7	218
32	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195
33	Kruppel-like factor 15 is a regulator of cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7074-7079.	7.1	186
34	MicroRNA Profiling Identifies MicroRNA-155 as an Adverse Mediator of Cardiac Injury and Dysfunction During Acute Viral Myocarditis. Circulation Research, 2012, 111, 415-425.	4.5	184
35	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	7.1	182
36	Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. Journal of Experimental Medicine, 2009, 206, 113-123.	8.5	180

#	Article	IF	Citations
37	Thrombospondin-2 Is Essential for Myocardial Matrix Integrity. Circulation Research, 2004, 95, 515-522.	4.5	179
38	Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding. Cells, 2020, 9, 242.	4.1	176
39	Integrating Cardiac PIP3 and cAMP Signaling through a PKA Anchoring Function of p110Î³. Molecular Cell, 2011, 42, 84-95.	9.7	174
40	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Associationâ€"European Society of Cardiology. European Heart Journal, 2018, 39, 4243-4254.	2.2	171
41	Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nature Reviews Cardiology, 2022, 19, 75-77.	13.7	171
42	Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovascular Research, 2004, 64, 24-31.	3.8	166
43	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. European Heart Journal, 2017, 38, 2649-2662.	2.2	163
44	Cardiac involvement in Churgâ€Strauss syndrome. Arthritis and Rheumatism, 2010, 62, 627-634.	6.7	158
45	Endothelial NADPH Oxidase-2 Promotes Interstitial Cardiac Fibrosis and Diastolic Dysfunction Through Proinflammatory Effects and Endothelial-Mesenchymal Transition. Journal of the American College of Cardiology, 2014, 63, 2734-2741.	2.8	154
46	Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp>orking <scp>G</scp>roup on <scp>M</scp>yocardial and <scp>P</scp>ericardial <scp>D</scp>iseases. European Journal of Heart Failure, 2021, 23, 512-526.	7.1	153
47	Loss or Inhibition of uPA or MMP-9 Attenuates LV Remodeling and Dysfunction after Acute Pressure Overload in Mice. American Journal of Pathology, 2005, 166, 15-25.	3.8	150
48	Disruption of the Plasminogen Gene in Mice Abolishes Wound Healing after Myocardial Infarction. American Journal of Pathology, 2000, 156, 1865-1873.	3.8	134
49	Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination. Science, 2018, 362, 1177-1182.	12.6	133
50	Regulatory RNAs in Heart Failure. Circulation, 2020, 141, 313-328.	1.6	133
51	Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias. European Heart Journal, 2018, 39, 864-873.	2.2	132
52	Hematopoietic miR155 Deficiency Enhances Atherosclerosis and Decreases Plaque Stability in Hyperlipidemic Mice. PLoS ONE, 2012, 7, e35877.	2.5	129
53	MicroRNA-221/222 Family Counteracts Myocardial Fibrosis in Pressure Overloadâ€"Induced Heart Failure. Hypertension, 2018, 71, 280-288.	2.7	128
54	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nature Cell Biology, 2013, 15, 1282-1293.	10.3	126

#	Article	IF	Citations
55	The RNA-binding protein HuR is essential for the B cell antibody response. Nature Immunology, 2015, 16, 415-425.	14.5	125
56	Increased Expression of Syndecan-1 Protects Against Cardiac Dilatation and Dysfunction After Myocardial Infarction. Circulation, 2007, 115, 475-482.	1.6	123
57	Treatments targeting inotropy. European Heart Journal, 2019, 40, 3626-3644.	2.2	123
58	TIMPs and cardiac remodeling: â€˜Embracing the MMP-independent-side of the familyâ€™. Journal of Molecular and Cellular Cardiology, 2010, 48, 445-453.	1.9	118
59	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	7.1	118
60	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2017, 19, 1361-1378.	7.1	115
61	Inflammation in viral myocarditis: friend or foe?. Trends in Molecular Medicine, 2012, 18, 426-437.	6.7	111
62	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	7.1	109
63	Relevance of cardiac parvovirus <scp>B19</scp> in myocarditis and dilated cardiomyopathy: review of the literature. European Journal of Heart Failure, 2016, 18, 1430-1441.	7.1	108
64	Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: Eosinophilic granulomatosis with polyangiitis and granulomatosis with polyangiitis. International Journal of Cardiology, 2015, 199, 170-179.	1.7	104
65	Mutations in MYH7 reduce the force generating capacity of sarcomeres in human familial hypertrophic cardiomyopathy. Cardiovascular Research, 2013, 99, 432-441.	3.8	102
66	Validation of the HFAâ€PEFF score for the diagnosis of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2020, 22, 413-421.	7.1	101
67	Inhibition of Urokinase-Type Plasminogen Activator or Matrix Metalloproteinases Prevents Cardiac Injury and Dysfunction During Viral Myocarditis. Circulation, 2006, 114, 565-573.	1.6	100
68	The microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis. European Heart Journal, 2015, 36, 2909-2919.	2.2	95
69	Replacement of the Muscle-Specific Sarcoplasmic Reticulum Ca 2+ -ATPase Isoform SERCA2a by the Nonmuscle SERCA2b Homologue Causes Mild Concentric Hypertrophy and Impairs Contraction-Relaxation of the Heart. Circulation Research, 2001, 89, 838-846.	4.5	93
70	Cardiac extracellular matrix remodeling: Fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). Journal of Molecular and Cellular Cardiology, 2010, 48, 544-549.	1.9	93
71	Absence of Thrombospondin-2 Causes Age-Related Dilated Cardiomyopathy. Circulation, 2009, 120, 1585-1597.	1.6	92
72	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	7.1	92

#	ARTICLE	IF	CITATIONS
73	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1287-1303.	3.8	91
74	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	7.1	90
75	A Deep Sequencing Approach to Uncover the miRNOME in the Human Heart. PLoS ONE, 2013, 8, e57800.	2.5	88
76	Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load. Antiviral Therapy, 2010, 15, 193-201.	1.0	86
77	Small but smart--microRNAs in the centre of inflammatory processes during cardiovascular diseases, the metabolic syndrome, and ageing. Cardiovascular Research, 2012, 93, 605-613.	3.8	83
78	Metabolic support for the heart: complementary therapy for heart failure?. European Journal of Heart Failure, 2016, 18, 1420-1429.	7.1	81
79	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	7.1	81
80	<i>microRNA-122</i> down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-Î²1 up-regulation. Clinical Science, 2014, 126, 497-506.	4.3	80
81	Microvascular and lymphatic dysfunction in HFpEF and its associated comorbidities. Basic Research in Cardiology, 2020, 115, 39.	5.9	77
82	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart â€˜OMicsâ€™ in AGEing (HOMAGE) randomized clinical trial. European Heart Journal, 2021, 42, 684-696.	2.2	77
83	Prognostic Relevance of Gene-Environment Interactions in Patients WithÂDilated Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 1313-1323.	2.8	76
84	Osteoglycin Prevents Cardiac Dilatation and Dysfunction After Myocardial Infarction Through Infarct Collagen Strengthening. Circulation Research, 2015, 116, 425-436.	4.5	75
85	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 43-59.	3.8	72
86	Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 359-379.	5.2	71
87	Syndecan-1 Amplifies Angiotensin IIâ€“Induced Cardiac Fibrosis. Hypertension, 2010, 55, 249-256.	2.7	69
88	Myocardial scar predicts monomorphic ventricular tachycardia but not polymorphic ventricular tachycardia or ventricular fibrillation in nonischemic dilated cardiomyopathy. Heart Rhythm, 2015, 12, 2106-2114.	0.7	67
89	Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy. European Journal of Heart Failure, 2010, 12, 227-231.	7.1	66
90	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€‘transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	7.1	66

#	Article	IF	Citations
91	Immunosuppressive Therapy Improves Both Short- and Long-Term Prognosis in Patients With Virus-Negative Nonfulminant Inflammatory Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004228.	3.9	65
92	Unraveling the Molecular Mechanism of Action of Empagliflozin in HeartÂFailure With Reduced Ejection Fraction WithÂorÂWithout Diabetes. JACC Basic To Translational Science, 2019, 4, 831-840.	4.1	65
93	Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood, 2000, 96, 1425-1432.	1.4	64
94	Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovascular Research, 2012, 94, 115-124.	3.8	64
95	Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1273-1280.	3.8	64
96	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	3.9	63
97	Sema3A promotes the resolution of cardiac inflammation after myocardial infarction. Basic Research in Cardiology, 2017, 112, 42.	5.9	62
98	Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences. European Heart Journal, 2021, 42, 162-174.	2.2	62
99	miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovascular Research, 2016, 110, 215-226.	3.8	61
100	Sexâ€specific associations of obesity and Nâ€terminal proâ€Bâ€type natriuretic peptide levels in the general population. European Journal of Heart Failure, 2018, 20, 1205-1214.	7.1	60
101	Matricellular Signaling Molecule CCN1 Attenuates Experimental Autoimmune Myocarditis by Acting as a Novel Immune Cell Migration Modulator. Circulation, 2010, 122, 2688-2698.	1.6	56
102	The diverse functions of osteoglycin: a deceitful dwarf, or a master regulator of disease?. FASEB Journal, 2016, 30, 2651-2661.	0.5	56
103	Long noncoding RNA<i>MALAT1</i>-derived mascRNA is involved in cardiovascular innate immunity. Journal of Molecular Cell Biology, 2016, 8, 178-181.	3.3	55
104	Imatinib Attenuates End-Organ Damage in Hypertensive Homozygous TGR(mRen2)27 Rats. Hypertension, 2006, 47, 467-474.	2.7	54
105	Inhibition of MicroRNA-146a and Overexpression of Its Target Dihydrolipoyl Succinyltransferase Protect Against Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction. Circulation, 2017, 136, 747-761.	1.6	53
106	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	3.8	51
107	RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection. American Journal of Transplantation, 2016, 16, 99-110.	4.7	49
108	Regulation of Cardiac Gene Expression by KLF15, a Repressor of Myocardin Activity. Journal of Biological Chemistry, 2010, 285, 27449-27456.	3.4	48

#	Article	IF	Citations
109	Renal function estimation and Cockcroftâ€“Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart â€˜OMicsâ€™ in AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. BMC Medicine, 2016, 14, 181.	5.5	48
110	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC: Heart Failure, 2021, 9, 268-277.	4.1	46
111	STAT3 activity is necessary and sufficient for the development of immuneâ€mediated myocarditis in mice and promotes progression to dilated cardiomyopathy. EMBO Molecular Medicine, 2013, 5, 572-590.	6.9	44
112	Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2011, 51, 318-328.	1.9	43
113	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proofâ€ofâ€concept, randomised, precisionâ€medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. European Journal of Heart Failure, 2020, 22, 1711-1723.	7.1	43
114	Thrombospondins in the heart: potential functions in cardiac remodeling. Journal of Cell Communication and Signaling, 2009, 3, 201-213.	3.4	42
115	Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice. PLoS ONE, 2016, 11, e0150236.	2.5	42
116	MicroRNAs Are Involved in End-Organ Damage During Hypertension. Hypertension, 2012, 60, 1088-1093.	2.7	41
117	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	7.1	41
118	Idiopathic dilated cardiomyopathy: possible triggers and treatment strategies. Netherlands Heart Journal, 2012, 20, 332-335.	0.8	40
119	Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biology, 2018, 66, 110-124.	3.6	39
120	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1805-1819.	3.8	39
121	Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. Journal of Experimental Medicine, 2007, 204, 1227-1235.	8.5	37
122	MicroRNAs and Beyond. Hypertension, 2009, 54, 1189-1194.	2.7	37
123	Cartilage intermediate layer protein 1 (CILP1): A novel mediator of cardiac extracellular matrix remodelling. Scientific Reports, 2017, 7, 16042.	3.3	37
124	Non-coding RNAs in vascular disease â€“ from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1281-1286.	3.8	37
125	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	7.1	37
126	Pathophysiology of <scp>T</scp>akotsubo syndromeÂâ€“Âa joint scientific statement from the Heart Failure Association <scp>T</scp>akotsubo Syndrome Study Group and Myocardial Function Working Group of the <scp>E</scp>uropean Society of CardiologyÂâ€“ÂPart 1: overview and the central role for catecholamines and sympathetic nervous system. European Journal of Heart Failure, 2022, 24, 257-273.	7.1	36

#	ARTICLE	IF	CITATIONS
127	The <scp>HFAâ€PEFF</scp> and <scp>H₂FPEF</scp> scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction. European Journal of Heart Failure, 2021, 23, 838-840.	7.1	35
128	Outcome and One Year Follow-up of Intra-arterial Staphylokinase in 191 Patients with Peripheral Arterial Occlusion. Thrombosis and Haemostasis, 2000, 83, 666-671.	3.4	34
129	Pathophysiology of Takotsubo syndromeÂâ€" a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of CardiologyÂâ€"ÂPart 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. European Journal of Heart Failure, 2022, 24, 274-286.	7.1	34
130	MicroRNA Involvement in Immune Activation During Heart Failure. Cardiovascular Drugs and Therapy, 2011, 25, 161-170.	2.6	31
131	Ventricular myocarditis coincides with atrial myocarditis in patients. Cardiovascular Pathology, 2016, 25, 141-148.	1.6	31
132	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	3.8	30
133	Myocarditis and heart failure: need for better diagnostic, predictive, and therapeutic tools. European Heart Journal, 2007, 28, 1279-1280.	2.2	29
134	A novel 72-kDa leukocyte-derived osteoglycin enhances the activation of toll-like receptor 4 and exacerbates cardiac inflammation during viral myocarditis. Cellular and Molecular Life Sciences, 2017, 74, 1511-1525.	5.4	28
135	Network integration and modelling of dynamic drug responses at multi-omics levels. Communications Biology, 2020, 3, 573.	4.4	28
136	Selective NADH communication from Î±-ketoglutarate dehydrogenase to mitochondrial transhydrogenase prevents reactive oxygen species formation under reducing conditions in the heart. Basic Research in Cardiology, 2020, 115, 53.	5.9	28
137	Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know. European Heart Journal, 2021, 42, 2384-2396.	2.2	28
138	NF-ÎºB-mediated metabolic remodelling in the inflamed heart in acute viral myocarditis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2579-2589.	3.8	27
139	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 2416-2433.	3.8	27
140	Immunometabolic mechanisms of heart failure with preserved ejection fraction. , 2022, 1, 211-222.		27
141	Functional Screening Identifies MicroRNAs as Multi-Cellular Regulators of Heart Failure. Scientific Reports, 2019, 9, 6055.	3.3	26
142	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). Biomarkers, 2020, 25, 201-211.	1.9	26
143	AMPKÎ±1 deletion in myofibroblasts exacerbates post-myocardial infarction fibrosis by a connexin 43 mechanism. Basic Research in Cardiology, 2021, 116, 10.	5.9	26
144	Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. European Heart Journal, 2013, 34, 1930-1941.	2.2	25

#	Article	IF	Citations
145	Colchicine aggravates coxsackievirus B3 infection in mice. International Journal of Cardiology, 2016, 216, 58-65.	1.7	25
146	Propionic acidemia as a cause of adult-onset dilated cardiomyopathy. European Journal of Human Genetics, 2017, 25, 1195-1201.	2.8	25
147	AntagomiR-103 and -107 Treatment Affects Cardiac Function and Metabolism. Molecular Therapy - Nucleic Acids, 2019, 14, 424-437.	5.1	25
148	MicroRNAs as Biomarkers for Ischemic Heart Disease. Journal of Cardiovascular Translational Research, 2013, 6, 458-470.	2.4	24
149	Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus <scp>B19</scp> persistence: a prospective, doubleâ€blind, randomized, placeboâ€controlled clinical trial. European Journal of Heart Failure, 2021, 23, 302-309.	7.1	24
150	Heart â€˜omicsâ€™ in AGEing (HOMAGE): design, research objectives and characteristics of the common database. Journal of Biomedical Research, 2014, 28, 349.	1.6	24
151	Differences in Virus Prevalence and Load in the Hearts of Patients with Idiopathic Dilated Cardiomyopathy with and without Immune-Mediated Inflammatory Diseases. Vaccine Journal, 2012, 19, 1182-1187.	3.1	23
152	Interactions between the extracellular matrix and inflammation during viral myocarditis. Immunobiology, 2012, 217, 503-510.	1.9	23
153	A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity. Archives of Toxicology, 2018, 92, 553-555.	4.2	23
154	cyNeo4j: connecting Neo4j and Cytoscape. Bioinformatics, 2015, 31, 3868-3869.	4.1	22
155	The forkhead transcription factor Foxo3 negatively regulates natural killer cell function and viral clearance in myocarditis. European Heart Journal, 2018, 39, 876-887.	2.2	22
156	Prevalence of Pathogenic Gene Mutations and Prognosis Do Not Differ in Isolated Left Ventricular Dysfunction Compared With Dilated Cardiomyopathy. Circulation: Heart Failure, 2018, 11, e004682.	3.9	22
157	MicroRNA-155 Amplifies Nitric Oxide/cGMP Signaling and Impairs Vascular Angiotensin II Reactivity in Septic Shock. Critical Care Medicine, 2018, 46, e945-e954.	0.9	22
158	SPARC preserves endothelial glycocalyx integrity, and protects against adverse cardiac inflammation and injury during viral myocarditis. Matrix Biology, 2018, 74, 21-34.	3.6	22
159	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	7.1	22
160	Association of left ventricular mass with the AGTR1 A1166C polymorphism. American Journal of Hypertension, 2012, 25, 472-478.	2.0	21
161	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	3.1	21
162	Arrhythmic risk stratification in non-ischaemic dilated cardiomyopathy beyond ejection fraction. Heart, 2020, 106, 656-664.	2.9	21

#	Article	IF	Citations
163	Global Longitudinal Strain is Incremental to Left Ventricular Ejection Fraction for the Prediction of Outcome in Optimally Treated Dilated Cardiomyopathy Patients. Journal of the American Heart Association, 2022, 11, e024505.	3.7	21
164	Heart Failure WithÂRecovered Ejection Fraction. Journal of the American College of Cardiology, 2018, 72, 1557-1558.	2.8	20
165	Extracellular SPARC increases cardiomyocyte contraction during health and disease. PLoS ONE, 2019, 14, e0209534.	2.5	19
166	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS caseâ€“control analyses. Clinical Research in Cardiology, 2020, 109, 22-33.	3.3	19
167	Postâ€discharge arrhythmic risk stratification of patients with acute myocarditis and lifeâ€threatening ventricular tachyarrhythmias. European Journal of Heart Failure, 2021, 23, 2045-2054.	7.1	17
168	Feasibility Study of Catheter-directed Thrombolysis with Recombinant Staphylokinase in Deep Venous Thrombosis. Thrombosis and Haemostasis, 1998, 79, 517-519.	3.4	17
169	The prognostic impact of mechanical atrial dysfunction and atrial fibrillation in heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2021, 23, 74-84.	1.2	17
170	A directed network analysis of the cardiome identifies molecular pathways contributing to the development of HFpEF. Journal of Molecular and Cellular Cardiology, 2020, 144, 66-75.	1.9	16
171	Biomarkerâ€based assessment of collagen crossâ€linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the <scp>HOMAGE</scp> clinical trial. European Journal of Heart Failure, 2022, 24, 321-331.	7.1	16
172	Lymphocytic myocarditis occurs with myocardial infarction and coincides with increased inflammation, hemorrhage and instability in coronary artery atherosclerotic plaques. International Journal of Cardiology, 2017, 232, 53-62.	1.7	15
173	Diagnostic value of echocardiographic markers for diastolic dysfunction and heart failure with preserved ejection fraction. Heart Failure Reviews, 2022, 27, 207-218.	3.9	15
174	Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Failure Reviews, 2017, 22, 765-773.	3.9	14
175	Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129. Non-coding RNA, 2019, 5, 31.	2.6	14
176	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2022, 43, 863-867.	2.2	14
177	Parvovirus-B19-associated fulminant myocarditis successfully treated with immunosuppressive and antiviral therapy. Antiviral Therapy, 2010, 15, 681-685.	1.0	13
178	Liver X receptor activation enhances CVB3 viral replication during myocarditis by stimulating lipogenesis. Cardiovascular Research, 2015, 107, 78-88.	3.8	13
179	Diagnostic approach of myocarditis: strike the golden mean. Netherlands Heart Journal, 2014, 22, 80-84.	0.8	12
180	Unlocking the Value of White Blood Cells for Heart Failure Diagnosis. Journal of Cardiovascular Translational Research, 2021, 14, 53-62.	2.4	12

#	Article	IF	Citations
181	The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial. European Journal of Heart Failure, 2022, 24, 1559-1568.	7.1	12
182	Factor XIII: the cement of the heart after myocardial infarction?. European Heart Journal, 2008, 29, 427-428.	2.2	11
183	Virus Infection of the Heart â€“ Unmet Therapeutic Needs. Antiviral Chemistry and Chemotherapy, 2012, 22, 249-253.	0.6	11
184	<scp>ESC</scp> Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. European Journal of Heart Failure, 2014, 16, 509-518.	7.1	11
185	CD45 is a more sensitive marker than CD3 to diagnose lymphocytic myocarditis in the endomyocardium. Human Pathology, 2017, 62, 83-90.	2.0	11
186	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	1.8	11
187	Identification of sexâ€specific biomarkers predicting newâ€onset heart failure. ESC Heart Failure, 2021, 8, 3512-3520.	3.1	11
188	High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. Mayo Clinic Proceedings, 2020, 95, 1158-1168.	3.0	10
189	Valproic acid stimulates myogenesis in pluripotent stem cell-derived mesodermal progenitors in a NOTCH-dependent manner. Cell Death and Disease, 2021, 12, 677.	6.3	10
190	NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction. Cardiovascular Research, 2022, 118, 2973-2984.	3.8	10
191	Neutrophil inhibition improves acute inflammation in a murine model of viral myocarditis. Cardiovascular Research, 2023, 118, 3331-3345.	3.8	10
192	Intravitreal injection of anti-miRs against miR-142-3p reduces angiogenesis and microglia activation in a mouse model of laser-induced choroidal neovascularization. Aging, 2021, 13, 12359-12377.	3.1	9
193	Fibrosis or hypertrophy: let TIMPs decide. Cardiovascular Research, 2014, 103, 196-197.	3.8	8
194	The Network Library: a framework to rapidly integrate network biology resources. Bioinformatics, 2016, 32, i473-i478.	4.1	8
195	The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model. Scientific Reports, 2020, 10, 15701.	3.3	8
196	Anthracycline-Related Heart Failure: Certain Knowledge and Open Questions. Current Heart Failure Reports, 2020, 17, 357-364.	3.3	8
197	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. Cardiovascular Diabetology, 2021, 20, 163.	6.8	7
198	Stabilin-1 mediates beneficial monocyte recruitment and tolerogenic macrophage programming during CVB3-induced viral myocarditis. Journal of Molecular and Cellular Cardiology, 2022, 165, 31-39.	1.9	7

#	Article	IF	Citations
199	Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the <scp>HOMAGE</scp> trial. European Journal of Heart Failure, 2022, 24, 771-778.	7.1	7
200	Integrated Analysis of Cancer Tissue and Vitreous Humor from Retinoblastoma Eyes Reveals Unique Tumor-Specific Metabolic and Cellular Pathways in Advanced and Non-Advanced Tumors. Cells, 2022, 11, 1668.	4.1	7
201	Balance of Active, Passive, and Anatomical Cardiac Properties in Doxorubicin-Induced Heart Failure. Biophysical Journal, 2019, 117, 2337-2348.	0.5	6
202	Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation. Journal of Cellular and Molecular Medicine, 2021, 25, 729-741.	3.6	6
203	Global longitudinal strain by <scp>CMR</scp> improves prognostic stratification in acute myocarditis presenting with normal <scp>LVEF</scp>. European Journal of Clinical Investigation, 2022, 52, .	3.4	6
204	Thrombospondin 1. Hypertension, 2011, 58, 770-771.	2.7	5
205	Lymphocytes Infiltrate the Quadriceps Muscle in Lymphocytic Myocarditis Patients: A Potential New Diagnostic Tool. Canadian Journal of Cardiology, 2014, 30, 1547-1554.	1.7	5
206	Toll-Like Receptors: Are They Taking a Toll on the Heart in Viral Myocarditis?. Viruses, 2021, 13, 1003.	3.3	5
207	The Missing â€œlncâ€•between Genetics and Cardiac Disease. Non-coding RNA, 2020, 6, 3.	2.6	5
208	Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from <scp>HOMAGE</scp> and the <scp>UK</scp> Biobank. European Journal of Heart Failure, 2022, 24, 976-984.	7.1	5
209	Peroxidasin-like protein: expanding the horizons of matrix biology. Cardiovascular Research, 2014, 101, 342-343.	3.8	4
210	Breeding Strategy Determines Rupture Incidence in Post-Infarct Healing WARPing Cardiovascular Research. PLoS ONE, 2015, 10, e0139199.	2.5	4
211	PD-(L)1 Inhibition and Cardiac Damage: A Relevant Toxicity?. Journal of Thoracic Oncology, 2018, 13, 478-479.	1.1	4
212	Resistance to retinopathy development in obese, diabetic and hypertensive ZSF1 rats: an exciting model to identify protective genes. Scientific Reports, 2018, 8, 11922.	3.3	4
213	Prednisone and azathioprine in patients with inflammatory cardiomyopathy: systematic review and metaâ€analysis. ESC Heart Failure, 2020, 7, 2278-2296.	3.1	4
214	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	3.0	4
215	Annexin A5 and the failing heart; lost or found in translation?. European Heart Journal, 2007, 28, 2695-2696.	2.2	3
216	Diastolic heart failure after acute myocarditis, a new discovery in inflammatory cardiomyopathies?. Heart, 2011, 97, 685-686.	2.9	3

#	Article	IF	Citations
217	A passionate endurance cyclist ultimately survives sudden death in right ventricular giant cell myocarditis. International Journal of Cardiology, 2014, 170, e74-e75.	1.7	3
218	Scientific updates on the interaction of genes, epigenetics, and multicellularity in cardiovascular diseases: the Working Group of Myocardial Function of the ESC. Cardiovascular Research, 2018, 114, 1271-1272.	3.8	3
219	Vascular ring anomaly in a patient with phosphomannomutase 2 deficiency: A case report and review of the literature. JIMD Reports, 2020, 56, 27-33.	1.5	3
220	Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood, 2000, 96, 1425-1432.	1.4	3
221	The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial. Journal of Cardiac Failure, 2021, , .	1.7	3
222	Letter by Pinto and Heymans Regarding Article, â€œAblation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Miceâ€ Circulation, 2008, 118, e697.	1.6	2
223	Response to Letter Regarding Article, â€œCirculating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Diseaseâ€ Circulation: Cardiovascular Genetics, 2011, 4, .	5.1	2
224	AAV9-mediated functional screening for cardioprotective cytokines in Coxsackievirus-B3-induced myocarditis. Scientific Reports, 2022, 12, 7304.	3.3	2
225	Meeting highlights from the 2013 <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation <scp>W</scp>inter <scp>M</scp>eeting on <scp>T</scp>ranslational <scp>H</scp>eart <scp>F</scp>ailure <scp>R</scp>esearch. European Journal of Heart Failure, 2014, 16, 6-14.	7.1	1
226	Response to â€˜The possible role of insulin and glucagon in patients with heart failure and Type 2 diabetesâ€™. European Heart Journal, 2020, 41, 326-327.	2.2	1
227	Small but Smart. , 2015, , 179-190.		1
228	CD40â€CD40 ligand (CD40L) signaling modulates cardiac hypertrophy in angiotensinâ€II induced hypertensive heart disease. FASEB Journal, 2013, 27, 1128.6.	0.5	1
229	Correlation of Volume of Macular Edema with Retinal Tomography Features in Diabetic Retinopathy Eyes. Journal of Personalized Medicine, 2021, 11, 1337.	2.5	1
230	100â€ƒGlobal longitudinal strain by CMR improves prognostic stratification in acute myocarditis presenting with normal LVEF. European Heart Journal Supplements, 2021, 23, .	0.1	1
231	Cardiomyocyte disintegration during Andersonâ€“Fabry's disease. European Heart Journal, 2010, 31, 917-917.	2.2	0
232	Perimyocarditis Complicated by Early Development ofÂConstrictive Pericarditis. Canadian Journal of Cardiology, 2016, 32, 395.e11-395.e12.	1.7	0
233	Reply to the letter to the editor â€œIs colchicine really harmful in viral myocarditis?â€ International Journal of Cardiology, 2017, 229, 43.	1.7	0
234	Lysosomal integral membrane protein 2 is a novel component of the cardiac intercalated disc and vital for load-induced cardiac myocyte hypertrophy. Journal of Cell Biology, 2007, 177, i5-i5.	5.2	0

#	Article	IF	Citations
235	The matricellular proteins thrombospondinâ€2, osteonectin and osteoglycin modulate cardiac inflammation, injury and function during viral myocarditis.. FASEB Journal, 2012, 26, 1060.6.	0.5	0
236	Role of Inflammation and Matrix Proteinases in Cardiac Remodeling Following Stress and Injury. , 2013, , 179-200.		0
237	Role of SPARC in Cardiac Extracellular Matrix Remodeling After Myocardial Infarction. , 2013, , 427-444.		0
238	Osteoglycin (OGN) modulates inflammation during viral myocarditis via an interaction with Toll Like Receptor 4.. FASEB Journal, 2013, 27, 829.1.	0.5	0